Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis
暂无分享,去创建一个
Shigeaki Suzuki | A. Uzawa | S. Kuwabara | M. Takahashi | K. Utsugisawa | Y. Nagane | T. Kubota | M. Samukawa | S. Konno | N. Kawaguchi | Yasushi Suzuki | M. Masuda | T. Sugimoto | N. Minami | M. Yasuda | G. Watanabe | Y. Ozawa | Hiroyuki Akamine | T. Kimura | Yosuke Onishi
[1] Shigeaki Suzuki,et al. Japan MG registry: Chronological surveys over 10 years , 2022, Clinical and Experimental Neuroimmunology.
[2] R. Govindarajan,et al. Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis , 2021, Medical science monitor : international medical journal of experimental and clinical research.
[3] J. Statland,et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial , 2021, The Lancet Neurology.
[4] A. Uzawa,et al. Long-term outcomes and prognostic factors in generalized myasthenia gravis , 2021, Journal of Neurology.
[5] F. Zimprich,et al. Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis , 2020, Neurology.
[6] A. Uzawa,et al. Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis , 2019, Journal of the Neurological Sciences.
[7] M. Freimer. Faculty Opinions recommendation of Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[8] Hidekazu Suzuki,et al. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] G. L. Masson,et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.
[10] M. Benatar,et al. Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.
[11] Hidekazu Suzuki,et al. Early fast‐acting treatment strategy against generalized myasthenia gravis , 2017, Muscle & nerve.
[12] M. Benatar,et al. International consensus guidance for management of myasthenia gravis , 2016, Neurology.
[13] Nils Erik Gilhus,et al. Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.
[14] H. Murai. Japanese clinical guidelines for myasthenia gravis: Putting into practice , 2015 .
[15] C. Montomoli,et al. Complete stable remission and autoantibody specificity in myasthenia gravis , 2013, Neurology.
[16] P. Vermersch,et al. Rituximab in refractory and non‐refractory myasthenia: A retrospective multicenter study , 2012, Muscle & nerve.
[17] K. Fujihara,et al. The MG‐QOL15 Japanese version: Validation and associations with clinical factors , 2012, Muscle & nerve.
[18] K. Fujihara,et al. [The MG-QOL15 Japanese version: validation and associations with clinical factors]. , 2012, Rinsho shinkeigaku = Clinical neurology.
[19] K. Fujihara,et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study , 2011, BMJ Open.
[20] Shigeaki Suzuki,et al. Early Aggressive Treatment Strategy against Myasthenia Gravis , 2010, European Neurology.
[21] D. Sanders,et al. Immunosuppressive therapies in myasthenia gravis , 2010, Autoimmunity.
[22] D. Sanders,et al. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.
[23] M. Pagala,et al. Lifetime course of myasthenia gravis , 2008, Muscle & nerve.
[24] D B Sanders,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.
[25] A. Lefvert,et al. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study , 1998, Acta neurologica Scandinavica.